Quest Diagnostics launched a novel prostate cancer biomarker test through its subspecialty pathology business, AmeriPath, in collaboration with Envision Sciences, an Australian-based clinical diagnostics company developing a pipeline of biomarker-based cancer diagnostic and prognostic tests in tissue and blood. The new, tissue-based test service is intended to address the pressing clinical need for tests to help identify and differentiate potentially aggressive cases of prostate cancer in men. Quest developed and validated the laboratory test under an intellectual property license agreement with Envision for use of Envision’s proprietary biomarker and immunohistochemistry technology, which includes Envision’s staining technology and novel biomarkers.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DGX:
- Quest Diagnostics launches first consumer-initiated genetic test
- Quest Diagnostics, Proov collaborate on home fertility test
- Quest Diagnostics initiated with a Neutral at Piper Sandler
- Quest Diagnostics Completes Acquisition of Haystack Oncology, Adding Sensitive MRD Liquid Biopsy Technology to Cancer Diagnostics Portfolio